Silence Therapeutics
1
9M
1
0.05
1
1
- Areas of investment
Summary
Silence Therapeutics appeared to be the Corporate Investor, which was created in 1999. The company was established in Europe in United Kingdom. The main office of represented Corporate Investor is situated in the London.
We can highlight the next thriving fund investment areas, such as Electronics, Biotechnology. Besides, a startup needs to be aged 11-15 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Arrowhead Pharmaceuticals.
The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 5 - 10 millions dollars. The increased amount of exits for fund were in 2000. The high activity for fund was in 2017.
The standard case for the fund is to invest in rounds with 1 partaker. Despite the Silence Therapeutics, startups are often financed by RA Capital Management, OrbiMed.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.05
- Investments by industry
- Pharmaceutical (1)
- Biotechnology (1)
- Nanotechnology (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 32
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.